SG10201500822XA - Production of proteins in glutamine-free cell culture media - Google Patents

Production of proteins in glutamine-free cell culture media

Info

Publication number
SG10201500822XA
SG10201500822XA SG10201500822XA SG10201500822XA SG10201500822XA SG 10201500822X A SG10201500822X A SG 10201500822XA SG 10201500822X A SG10201500822X A SG 10201500822XA SG 10201500822X A SG10201500822X A SG 10201500822XA SG 10201500822X A SG10201500822X A SG 10201500822XA
Authority
SG
Singapore
Prior art keywords
glutamine
proteins
production
cell culture
culture media
Prior art date
Application number
SG10201500822XA
Inventor
Martin Gawlitzek
Christina Teresa Petraglia
Shun Luo
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US23288909P priority Critical
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG10201500822XA publication Critical patent/SG10201500822XA/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42771984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201500822X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • C12N5/0043Medium free of human- or animal-derived components
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/32Amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/32Amino acids
    • C12N2500/33Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/90Serum-free medium, which may still contain naturally-sourced components
SG10201500822XA 2009-08-11 2010-08-06 Production of proteins in glutamine-free cell culture media SG10201500822XA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US23288909P true 2009-08-11 2009-08-11

Publications (1)

Publication Number Publication Date
SG10201500822XA true SG10201500822XA (en) 2015-04-29

Family

ID=42771984

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201901417UA SG10201901417UA (en) 2009-08-11 2010-08-06 Production of proteins in glutamine-free cell culture media
SG10201500822XA SG10201500822XA (en) 2009-08-11 2010-08-06 Production of proteins in glutamine-free cell culture media
SG2012009429A SG178358A1 (en) 2009-08-11 2010-08-06 Production of proteins in glutamine-free cell culture media

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201901417UA SG10201901417UA (en) 2009-08-11 2010-08-06 Production of proteins in glutamine-free cell culture media

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012009429A SG178358A1 (en) 2009-08-11 2010-08-06 Production of proteins in glutamine-free cell culture media

Country Status (16)

Country Link
US (7) US8512983B2 (en)
EP (2) EP3431588A1 (en)
JP (3) JP5930542B2 (en)
KR (4) KR20180105258A (en)
CN (2) CN104059955A (en)
AU (3) AU2010282733B2 (en)
BR (1) BR112012002974A2 (en)
CA (1) CA2770690A1 (en)
HK (1) HK1202588A1 (en)
IL (2) IL217752D0 (en)
MX (2) MX2012001742A (en)
NZ (1) NZ598677A (en)
RU (2) RU2017138926A (en)
SG (3) SG10201901417UA (en)
WO (1) WO2011019619A1 (en)
ZA (1) ZA201200763B (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
US8859229B2 (en) * 2007-02-02 2014-10-14 Yale University Transient transfection with RNA
WO2011019619A1 (en) 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
WO2011065940A1 (en) * 2009-11-24 2011-06-03 Biogen Idec Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
KR20140014102A (en) 2010-12-01 2014-02-05 앨더바이오 홀딩스 엘엘씨 Anti-ngf compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013059405A1 (en) 2011-10-18 2013-04-25 Coherus Biosciences, Inc. Etanercept formulations stabilized with amino acids
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9493744B2 (en) 2012-06-20 2016-11-15 Genentech, Inc. Methods for viral inactivation and other adventitious agents
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2883272A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
RU2518329C1 (en) * 2012-12-07 2014-06-10 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") Method of production of substance recombinant human erythropoietin and nanocapsular form of recombinant human erythropoietin with use of substance obtained by this method
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US10017732B2 (en) 2013-03-15 2018-07-10 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
BR112015022529A2 (en) * 2013-03-15 2017-07-18 Genentech Inc cell culture media and antibody production processes
IN2013MU02285A (en) * 2013-07-06 2015-06-19 Cadila Healthcare Limited improved process for production of monoclonal antibodies
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US8859252B1 (en) 2014-01-02 2014-10-14 Aerial Biopharma, Llc Prostatic acid phosphatase, compositions comprising the same, and methods for producing and/or purifying the same
US20170166941A1 (en) * 2014-01-29 2017-06-15 Lg Life Sciences Ltd. Method for modulating galactosylation of recombinant protein through optimization of culture medium
EP3099324A4 (en) * 2014-01-30 2017-07-12 Coherus Biosciences, Inc. Perfusion media
DK3122869T3 (en) * 2014-03-24 2019-09-09 Biogen Ma Inc Procedures for reducing glutamine depression in mammal culture culture
WO2015163783A1 (en) * 2014-04-25 2015-10-29 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Method of producing a recombinant human erythropoietin substance and a nanoencapsulated form of recombinant human erythropoietin using the substance produced by said method
US20170327787A1 (en) * 2014-07-16 2017-11-16 Heartseed Inc. New undifferentiated stem cell removal and myocardial purification and refinement culture medium
WO2018002036A1 (en) 2016-06-28 2018-01-04 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
KR20180047404A (en) * 2016-10-31 2018-05-10 삼성바이오에피스 주식회사 Process for reducing undesirable by-product in cell culture
KR101932137B1 (en) * 2017-01-02 2018-12-24 연세대학교 산학협력단 Compositions for increasing glycosylayion and methods for producing proteins with increased glycosylation

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049494A (en) * 1975-09-04 1977-09-20 The United States Of America As Represented By The Secretary Of Agriculture Vaccine production process
FR2413974B1 (en) 1978-01-06 1982-12-03 David Bernard
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5185259A (en) 1982-05-05 1993-02-09 Genentech, Inc. Truncated human tissue plasminogen activator
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4853330A (en) 1983-04-07 1989-08-01 Genentech, Inc. Human tissue plasminogen activator
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
IE56716B1 (en) 1983-01-19 1991-11-20 Genentech Inc Method for producing human tpa and expression vectors therefor
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
FR2539642B1 (en) 1983-01-20 1985-12-13 Choquenet Sa L Filter press including sludge extraction means
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035D0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
JPH04501201A (en) 1987-12-21 1992-03-05
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
WO1989008114A1 (en) 1988-02-25 1989-09-08 The General Hospital Corporation Rapid immunoselection cloning method
US4861579A (en) 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
AT113846T (en) 1988-06-21 1994-11-15 Genentech Inc Therapeutic compositions for the treatment of myocardial infarction.
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
JP2783294B2 (en) 1988-09-23 1998-08-06 カイロン コーポレーション Enhanced cell proliferation, cell culture medium for culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag Bispecific, oligo, mono- and oligovalent antikoerperkonstrukte, their production and use
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
DK168302B1 (en) 1989-06-29 1994-03-07 Danisco A process for the introduction of molecules, particularly genetic material into plant cells
GB2237288A (en) * 1989-10-18 1991-05-01 Celltech Ltd Amplification of a heterologous gene in recombinant eukaryotic host cells
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU653927B2 (en) * 1990-01-22 1994-10-20 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Co-independent growth medium for maintenance and propagation of cells
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DK0564531T3 (en) 1990-12-03 1998-09-28 Genentech Inc Enrichment process of variant proteins with altered binding properties
DE69233254T2 (en) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanized antibodies heregulin
DK1260521T3 (en) 1991-08-14 2008-03-25 Genentech Inc Immunoglobulinvarianter of specific Fc-
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH07501451A (en) 1991-11-25 1995-02-16
CA2129663C (en) 1992-02-06 2005-07-05 James S. Huston Biosynthetic binding protein for cancer marker
EP0655924A4 (en) 1992-06-30 1996-09-11 Oncologix Inc A COMBINATION OF ANTI-erbB-2 MONOCLONAL ANTIBODIES AND METHOD OF USING.
JPH08500826A (en) 1992-08-21 1996-01-30 ジェネンテク,インコーポレイテッド Method of treating Lfa-1 mediated diseases
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
NZ258392A (en) 1992-11-13 1997-09-22 Idec Pharma Corp Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5417972A (en) 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
AT157455T (en) 1993-12-10 1997-09-15 Genentech Inc Methods to diagnose allergy testing and anti-allergic therapeutic agents
DK0739214T3 (en) 1994-01-18 1998-10-07 Genentech Inc A method for the treatment of parasitic infections using IgE antagonists
US5707622A (en) 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9506249D0 (en) 1995-03-27 1995-05-17 Karobio Ab Media for insect cell cultures
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE69637481T2 (en) 1995-04-27 2009-04-09 Amgen Fremont Inc. Dating from immunized Xenomäusen human antibodies to IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc Antibody and antibody fragments for inhibiting the growth of tumors
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
CA2242414C (en) 1996-01-23 2012-01-03 Genentech, Inc. Anti-cd18 antibodies for use against stroke
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
IL130143D0 (en) 1996-11-27 2000-06-01 Genentech Inc Humanized anti-CD11a antibodies
AT387495T (en) 1996-12-03 2008-03-15 Amgen Fremont Inc Fully human antibodies bind egfr
US20020041847A1 (en) 1998-03-12 2002-04-11 Goldenberg David M. Immunotherapy of malignant and autoimmune disorders in domestic animals using naked antibodies, immunoconjugates and fusion proteins
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
DE69829891T2 (en) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF antibody
DK0981618T4 (en) 1997-05-15 2011-11-21 Genentech Inc Anti-Apo-2 antibody
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
AU757627B2 (en) 1997-06-24 2003-02-27 Genentech Inc. Methods and compositions for galactosylated glycoproteins
US6368596B1 (en) 1997-07-08 2002-04-09 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
JP2001521909A (en) 1997-10-31 2001-11-13 ジェネンテク・インコーポレイテッド The methods and compositions comprising the glycoprotein glycoform
IL136544D0 (en) 1997-12-05 2001-06-14 Scripps Research Inst Humanization of murine antibody
AU2112199A (en) * 1998-01-12 1999-07-26 Betagene, Inc. Recombinant cell lines for drug screening
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
IL138608D0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
DE69942021D1 (en) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improved antibody-dependent cell-mediated cytotoxicity
KR101063278B1 (en) 1998-08-11 2011-09-07 바이오겐 아이덱 인크. Drugs Comprising Anti-CD20 Antibodies for Treating Cell-Cell Lymphomas
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
WO2000027433A1 (en) 1998-11-09 2000-05-18 Idec Pharmaceuticals Corporation Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transplants
CN1191850C (en) 1998-11-09 2005-03-09 Idec药物公司 Treatment of hemoatological malignancies associated with circulating tumor cells using chimeric anti -CD20 antibody
HU0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
EP1035172A3 (en) 1999-03-12 2002-11-27 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
DE60032349T2 (en) 1999-04-26 2007-07-12 Genentech, Inc., South San Francisco Cell culture method for glycoproteins
AU777970C (en) 1999-05-07 2006-08-17 F. Hoffman-La Roche Ag Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
AU782160B2 (en) 1999-06-09 2005-07-07 Immunomedics Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
ITMI991299A1 (en) 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche Use of antibodies against surface antigens for the treatment of graft versus host disease
DE19930748C2 (en) 1999-07-02 2001-05-17 Infineon Technologies Ag A process for the manufacture of EEPROM and DRAM grave memory cell regions on a chip
CN1373672A (en) 1999-07-12 2002-10-09 杰南技术公司 Blocking immune response to foreign antigen using antagonist which binds to CD20
AU784971B2 (en) 1999-08-11 2006-08-10 Biogen Inc. Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
WO2001013945A1 (en) 1999-08-23 2001-03-01 Biocrystal Ltd. Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
BR0015224A (en) 1999-10-29 2002-07-09 Genentech Inc anti-antigen antibody prostate stem cell (PSCA) isolated anti-PSCA monoclonal antibody isolated nucleic acid, expression vector, cell, host cell, antibody production method, composition vitro method for killing a cancer cell expressing PSCA , use of an anti-PSCA monoclonal antibody and industrial article
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
EP1305045A1 (en) 2000-07-12 2003-05-02 Idec Pharmaceuticals Corporation Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
US20030185796A1 (en) 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
IL151906D0 (en) 2000-03-24 2003-04-10 Chiron Corp Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2
EP1463524A4 (en) 2001-12-07 2005-02-09 Chiron Corp Methods of therapy for non-hodgkin s lymphoma
CN1441677A (en) 2000-03-31 2003-09-10 Idec药物公司 Combined use of anti-cytokine antibodies or antagonists and anti-CD2O for treatment of B cell lymphoma
ES2528794T3 (en) 2000-04-11 2015-02-12 Genentech, Inc. multivalent antibodies and uses thereof
JP2003531178A (en) 2000-04-25 2003-10-21 アイデック ファーマスーティカルズ コーポレイション Intrathecal administration of rituximab for the central nervous system lymphoma treatment
AU6836301A (en) 2000-06-20 2002-01-02 Idec Pharma Corp Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
AT440618T (en) 2000-06-22 2009-09-15 Univ Iowa Res Found Combination of CpG and antikírpern against CD19, CD20, CD22 or CD40 for the prevention or treatment of cancer.
WO2002022212A2 (en) 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
US20020128448A1 (en) 2000-10-20 2002-09-12 Idec Pharmaceuticals Corporation Variant IgG3 Rituxan and therapeutic use thereof
EA007388B1 (en) 2001-01-29 2006-10-27 Идек Фармасьютикалз Корпорейшн The modified antibodies and methods of using
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20030103971A1 (en) 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
JP2005505240A (en) * 2001-02-15 2005-02-24 セントカー・インコーポレーテツド Chemical synthetic medium for the cultured mammalian cells
AU2002250352C1 (en) 2001-04-02 2009-04-30 Genentech, Inc. Combination therapy
EP1383800A4 (en) 2001-04-02 2004-09-22 Idec Pharma Corp RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII
WO2003061694A1 (en) 2001-05-10 2003-07-31 Seattle Genetics, Inc. Immunosuppression of the humoral immune response by anti-cd20 antibodies
JP2005515161A (en) 2001-06-14 2005-05-26 インターミューン インコーポレイテッド Combination therapy of γ- interferon and B cell-specific antibodies
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
KR20100018071A (en) 2001-08-03 2010-02-16 글리카트 바이오테크놀로지 아게 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US20050070689A1 (en) * 2001-08-03 2005-03-31 Genentech, Inc. Taci and br3 polypeptides and uses thereof
US7718387B2 (en) 2001-09-20 2010-05-18 Board Of Regents, The University Of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
EP2348043A1 (en) 2001-10-02 2011-07-27 Genentech, Inc. APO-2 ligand variants and uses thereof
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
RU2004127458A (en) 2002-02-14 2005-10-27 Иммуномедикс, Инк. (Us) Anti-cd20 antibodies, fusion proteins and methods of use thereof
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
KR20050000380A (en) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 Cells with modified genome
US20030219818A1 (en) 2002-05-10 2003-11-27 Bohen Sean P. Methods and compositions for determining neoplastic disease responsiveness to antibody therapy
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005083058A1 (en) * 2004-03-01 2005-09-09 Ares Trading S.A. Use of a serum-free cell culture medium for the production of il-18bp in mammalian cells
CN100537751C (en) * 2004-05-12 2009-09-09 华东理工大学 Serum-free medium suitable to culturing ovary cells of Chinese hamster
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
DOP2006000029A (en) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and use thereof. (Variants of an antibody and uses thereof)
US20100166741A1 (en) 2006-07-13 2010-07-01 Genentech , Inc. Altered br-3 binding polypeptides
ES2392701T3 (en) * 2007-05-11 2012-12-13 Amgen Inc. Improved media feeding
CN101226138B (en) * 2008-02-04 2010-06-09 杭州华锦药业有限公司 Method for detecting activity of hepatocyte auxin
WO2011019619A1 (en) 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
US9813410B2 (en) 2014-06-26 2017-11-07 Rakuten, Inc. Information processing apparatus, information processing method, and information processing program

Also Published As

Publication number Publication date
IL217752D0 (en) 2012-03-29
AU2016238859A1 (en) 2016-10-27
US20160024217A1 (en) 2016-01-28
WO2011019619A1 (en) 2011-02-17
AU2010282733A1 (en) 2012-03-01
RU2012108843A (en) 2013-09-20
JP6411324B2 (en) 2018-10-24
CN102498206A (en) 2012-06-13
JP2016116521A (en) 2016-06-30
US9714293B2 (en) 2017-07-25
AU2019201603A1 (en) 2019-04-04
KR20120088667A (en) 2012-08-08
US20190023800A1 (en) 2019-01-24
JP5930542B2 (en) 2016-06-08
BR112012002974A2 (en) 2015-09-01
US8512983B2 (en) 2013-08-20
KR20180114966A (en) 2018-10-19
US20140024078A1 (en) 2014-01-23
HK1202588A1 (en) 2015-10-02
AU2016238859B2 (en) 2018-12-13
MX355650B (en) 2018-04-26
US20180148510A1 (en) 2018-05-31
NZ598677A (en) 2014-06-27
JP2018134079A (en) 2018-08-30
KR101822205B1 (en) 2018-01-25
CA2770690A1 (en) 2011-02-17
RU2017138926A (en) 2019-02-11
SG10201901417UA (en) 2019-03-28
MX2012001742A (en) 2012-03-21
KR20180105258A (en) 2018-09-27
SG178358A1 (en) 2012-03-29
EP2464725A1 (en) 2012-06-20
JP2013501522A (en) 2013-01-17
AU2010282733B2 (en) 2016-07-14
EP3431588A1 (en) 2019-01-23
CN104059955A (en) 2014-09-24
RU2639288C2 (en) 2017-12-20
US20190263921A1 (en) 2019-08-29
ZA201200763B (en) 2013-07-31
US20110091936A1 (en) 2011-04-21
US20170283505A1 (en) 2017-10-05
KR20180010324A (en) 2018-01-30
IL264336D0 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
DK2718422T3 (en) Culture media for stem cells
IL220219D0 (en) Rna preparations comprising purified modified rna for reprogramming cells
ZA201201220B (en) Differentiation of human embryonic stem cells
IL217257A (en) Method of producing erythrocytes without feeder cells
GB2458863B (en) Improved culture of stem cells
SG10201501513TA (en) Culture additives to boost stem cell proliferation and differentiation response
LT3144389T (en) Making and using in vitro-synthesized ssrna for introducing into mammalian cells to induce a biological or biochemical effect
GB0703188D0 (en) Large scale production of stem cells
EP2756071A4 (en) Media supplements and methods to culture human gastrointestinal anaerobic microorganisms
BR112012009921A2 (en) methods for reprogramming cells and their uses
AU2011246502A1 (en) Improved cell cultivation process
BR112013033730A2 (en) mammalian cell culture
EP2516625A4 (en) Differentiation of human embryonic stem cells
PL2393917T3 (en) Culture medium for epithelial stem cells and organoids comprising said stem cells.
EP2417244A4 (en) Production of commercial biodiesel from genetically modified microorganisms
ZA201306708B (en) Host cells and methods for production of isobutanol
EP2391711A4 (en) Novel cell lines and methods
HK1177950A1 (en) Oligopeptide-free cell culture media
PL2046946T3 (en) Pluripotent stem cell culture
PL2366021T3 (en) Pluripotent stem cell culture on micro-carriers
EP2681306A4 (en) Cell culture system
AU2016202260A1 (en) Differentiation of human embryonic stem cells
IL261851D0 (en) Reprogramming t cells and hematopoietic cells
EP2421956A4 (en) Compositions and methods for deriving or culturing pluripotent cells
HK1188466A1 (en) Plant derived cell culture material